High Prevalence of Latent Tuberculosis Infection in Patients in End-Stage Renal Disease on Hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and Tuberculin Skin Test
- 537 Downloads
Individuals with end-stage renal disease (ESRD) are 10- to 25-fold more likely than immunocompetent people to develop active tuberculosis (TB) and are candidates for being treated for latent TB infection (LTBI). However, diagnosis using the tuberculin skin test (TST) is doubly difficult due to cutaneous anergy and cross-reactions with Bacille–Calmette–Guérin (BCG) vaccination.
Materials and Methods:
This was a prospective, doublematched, cohort study in which 32 ESRD patients and 32 age-matched, healthy controls were enrolled. The TST and two new interferon-γ blood tests, QuantiFERON-TB Gold (QFT-G) and T-SPOT.TB (ELISPOT), were performed. The subjects were followed up 2 years for active TB disease. ELISPOT was done in ESRD patients only.
Compared to the healthy controls, a high prevalence of LTBI was found in the ESRD patients by TST (62.5%, 95% confidence interval [CI] 43.7–78.9), QFT-G (40.0%, 95% CI 22.7–59.4), and ELISPOT (46.9%, 95% CI 29.1–65.3). Agreement was moderate (kappa [κ] = 0.53) for QFT-G and ELISPOT but only slight between TST and QFT-G (κ = 0.25) and fair between TST and ELISPOT (κ = 0.32). ESRD (p = 0.03) and diabetes mellitus (p = 0.04) were significant risk factors for QFT-G positivity on the multivariable analysis. The overall rate of active TB was 1.66 cases per 100 person-years (pys), with the rate higher in patients with ESRD (3.53 per 100 pys) and those with positive (3.40 per 100 pys) and indeterminate QFT results (30.16 per 100 pys), although the difference was not statistically significant. Sensitivity, specificity, and positive and negative predictive values of QFT-G for active TB was 100%, 62.1%, 8.3% and 100%.
This pilot study is the first to compare QFT-G, ELISPOT, and TST in ESRD patients on hemodialysis and demonstrates a high prevalence of LTBI in this population. In our study, the QFT-G was the more accurate method for identifying those truly infected with Mycobacterium tuberculosis, even in BCG-vaccinated individuals.
KeywordsTuberculin Skin Test Respir Crit ESRD Patient Nephrol Dial Transplant Latent Tuberculosis Infection
Unable to display preview. Download preview PDF.
- 1.WHO. 2007 WHO Fact Sheet. Available at: http://www.who.int/tb/publications/2007/factsheet_2007.pdf. Accessed 15 July 2007.
- 2.CDC Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221–S247.Google Scholar
- 13.Centers for Disease Control and Prevention (CDC): Tuberculosis transmission in a renal dialysis center — Nevada, 2003. MMWR Morb Mortal Wkly Rep 2004; 53: 873–875.Google Scholar
- 15.Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V: The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005; 20: 2720–2724.PubMedCrossRefGoogle Scholar
- 21.Kunimoto D, Birse T, Lindemulder A, Manning T, Miedzinski L, Saxinger L, Shafran S, Taylor G, Houston S. QuantiFERON-TB Gold testing of HIV patients for latent TB infection. Can J infect Dis Med Microbiol 2006; 17.Google Scholar
- 25.Cellestis Ltd.: QuantiFERON®-TB Gold Analysis Software. Available at: http://www.cellestis.com/IRM/content/aust/SoftwareDownloadAU.aspx. Accessed 24 July 2007.
- 26.CDC-Taiwan: Taiwan guideline on TB diagnosis and treatment. In: CDC-Taiwan (eds): 2nd edn. Taiwan Centers for Disease Control, Taipei 2006.Google Scholar
- 33.Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328–1334.PubMedCrossRefGoogle Scholar
- 34.Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D’Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L: Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631–635.PubMedCrossRefGoogle Scholar